In summary, our in vivo and in vitro findings, together with the clinical data of patients with IPF, provide evidence that miR-30a upregulation could downregulate the expression level of its target gene TET1 and exert antifibrotic effect and protective function against pulmonary injury. The gene discussed is TET1; the disease is idiopathic pulmonary fibrosis.